Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451847 | 1.00 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL12021080 | 1.00 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL25842985 | 0.89 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL14001868 | 0.86 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL2688456 | 0.84 | ALDH1A1 (0.40) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL2688457 | 0.84 | ALDH1A1 (0.40) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL2688459 | 0.84 | ALDH1A1 (0.40) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL3604748 | 0.84 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL19958804 | 0.84 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL15356409 | 0.84 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920093-B2 | Dimeric IAP inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20160355547-A1 | Dimeric IAP Inhibitors | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160052965-A1 | Dimeric IAP Inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2016-02-25 | — | — | US | disclosed |
| US-9187490-B2 | Dimeric IAP inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329823-A1 | Dimeric IAP Inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8822525-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| EP-1851200-B1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20130289042-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8497297-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110301151-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2011-12-08 | — | — | US | disclosed |
| EP-2385038-A1 | Dimeric IAP inhibitors | Tetralogic Pharmaceuticals Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| US-8022230-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100075911-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7517906-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060194741-A1 | Dimeric IAP inhibitors | MEDIVIR AB (SE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075911-A1 | DIMERIC IAP INHIBITORS | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
| US-20110301151-A1 | DIMERIC IAP INHIBITORS | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
| US-20140329823-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
| US-20160052965-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
| US-20060194741-A1 | Dimeric IAP inhibitors | BIRC2, BIRC3, BIRC5 | HSD17B10 2998/4885SMN1; SMN2 728/4885ALDH1A1 4440/4885 |
| US-20160355547-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
| US-20130289042-A1 | DIMERIC IAP INHIBITORS | BIRC2, XIAP, BIRC5 | HSD17B10 3446/4885SMN1; SMN2 537/4885ALDH1A1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.